Navigation Links
Afid Therapeutics Obtains Positive Evaluation of its Triple Mode,Viral Sequestration Agents

LANSING, Mich., March 27, 2007 /PRNewswire/ -- Afid Therapeutics, Inc. announced that it received positive results on the ability of its new triple mode viral sequestration agents to block viral infections of mammalian cells. The audited results were obtained from a specialized, independent third party testing organization. The new viral sequestrating agents are designed to bind and inactivate viruses by 3 critical mechanisms thus blocking infection. They are aimed at viruses responsible for common causes of influenza in addition to SARS, bird flu and other avian influenzas. "Carbohydrate interactions are critical to the infection process in these systems. The technology capitalizes on the companies' rich carbohydrate chemistry technology portfolio and expertise," said Afid Founder and President Rawle Hollingsworth. Dr. Hollingsworth is a world authority on carbohydrate chemistry and holds nearly 50 issued US patents, scores of international patents and well over 100 publications on many aspects of carbohydrate chemistry critical to the success of the effort. The company intends to pursue both therapeutic and non- therapeutic applications. "The chemistry can be done easily enough that applications in public health, environmental, personal care and defense arenas are well within reach," adds Hollingsworth. "There are no real obstacles to scaling up," said Dr. Li Gao, Afid's research director.

Afid Therapeutics, Inc. was the first start-up firm to receive support from the "Rational Siting Push-Pull Accelerator" (RSPPA) grant to Michigan State University (MSU) from the Michigan Technology Tri-Corridor. The company recently received a $1.66M award from the Michigan 21st Century Jobs Creation Fund. It specializes in advanced chemistry based on carbohydrates with a focus on the drug discovery and development areas and provides advanced chemical intermediates to over 50 pharmaceutical clients around the world.< /p>

CONTACT: Dr. Rawle I. Hollingsworth +1-517-336-4663, Fax +1-517-324-1912, rih@afidtherapeutics.com

Web site: http://www.afidtherapeutics.com/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... 2016  NOIT™ Research LLC, a private, leading-edge autism ... campaign to assist needy families in obtaining one of ... between February 10, 2016 and March 31, 2016, the ... The NOIT is an auditory stimulus that plays a ... skills. Beth Shier , NOIT Research ...
(Date:2/11/2016)... Conn. , Feb. 11, 2016  AfterPill.com is ... to recommend alcohol abstinence for all women who are ... in the U.S. each year and raises the risks ... --> --> According to the Guttmacher ... 70% of women of child-bearing age, who have sex ...
(Date:2/11/2016)... Iowa , 11 de fevereiro de 2016 ... inauguração de sua fábrica de soroalbumina bovina (BSA ... Zelândia. A fábrica fica na Ilha Norte da ... "), desenvolvido e estabelecido na fábrica da Proliant ... . O projeto e instalação dos equipamentos ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, Texas, ... real facts surrounding all those Bible stories. For generations families have gathered to hear ... says there is more to these than just mere “stories”. , The article ...
(Date:2/12/2016)... ... ... of restorative dentistry, to date there has been no other option in the U.S. to ... is a now a new protocol in stopping cavity progression; Silver Diamine Fluoride (SDF). ... The application is as simple as drying the tooth and applying the SDF to ...
(Date:2/11/2016)... ... February 11, 2016 , ... “ HEALING MIND : ... Well Managed Mind” (published by Balboa Press) teaches readers how to become their own ... profound love, author Janice McDermott, M.Ed., LCSW, offers an understanding of how to heal ...
(Date:2/11/2016)... Oregon (PRWEB) , ... February 11, 2016 , ... ... campus participated in the American Osteopathic Association’s (AOA) Match Program Tuesday, February 9, ... Match Program places students into osteopathic graduate medical education positions across the country. ...
(Date:2/11/2016)... ... February 11, 2016 , ... Florida Hospital presents Heart Health Awareness ... St. Louis Blues at the Amalie Arena. The puck drops at 6:00pm, but fans ... the MEGA Heart, prior to the game. The MEGA Heart will be located on ...
Breaking Medicine News(10 mins):